Inrebic

Generic name: Fedratinib
Drug class: Multikinase inhibitors

Usage of Inrebic

Inrebic is a prescription medicine used to treat myelofibrosis in adults.

Myelofibrosis is a rare type of bone marrow cancer that affects your body's ability to produce blood cells.

It is not known if Inrebic is safe and effective in children.

Inrebic side effects

Get emergency medical help if you have signs of an allergic reaction to Inrebic: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some people using Inrebic have developed vitamin B1 deficiency that resulted in serious and sometimes fatal brain damage. Seek emergency medical attention if you have symptoms such as:

drowsiness, confusion, memory problems;

vision problems, unusual eye movements; or

problems with coordination and muscle movement.

Call your doctor at once if you have:

severe or ongoing nausea, vomiting, or diarrhea (even while you are taking medication to prevent these effects);

easy bruising, unusual bleeding, purple or red spots under your skin;

low red blood cells (anemia) - pale skin, unusual tiredness, feeling light-headed or short of breath, cold hands and feet; or

low white blood cell counts - fever, mouth sores, skin sores, sore throat, cough, trouble breathing.

You may need a blood transfusion if your blood counts get too low.

Common Inrebic side effects may include:

nausea, vomiting;

diarrhea; or

anemia.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Inrebic

To make sure Inrebic is safe for you, tell your doctor if you have ever had:

low levels of platelets or red blood cells;

liver disease;

kidney disease; or

if you have been taking ruxolitinib (Jakafi).

It is not known whether fedratinib will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.

You should not breastfeed while using Inrebic, and for at least 1 month after your last dose.

Relate drugs

How to use Inrebic

Usual Adult Dose for Myelofibrosis:

For patients with a baseline platelet count of 50 x 109/L or greater: 400 mg orally once a day Management of thiamine levels and Wernicke's encephalopathy (WE): -Assess thiamine levels and nutritional status prior to starting therapy, periodically during therapy, and as indicated. -Do not initiate this drug in patients with thiamine deficiency; replete thiamine prior to therapy initiation and during therapy if thiamine levels are low. -If Wernicke's encephalopathy is suspected, immediately discontinue therapy and initiate parenteral thiamine treatment. -Monitor until symptoms resolve or improve and thiamine levels normalize. Use: For the treatment of intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF)

Warnings

Some people using Inrebic have developed vitamin B1 deficiency that resulted in serious and sometimes fatal brain damage. Your vitamin B1 levels will need to be checked before and during treatment, and you may need to take a vitamin B1 supplement.

Get emergency medical help if you have symptoms such as drowsiness, confusion, memory problems, vision problems, unusual eye movements, or problems with coordination and muscle movement.

Call your doctor if you are sick with vomiting or diarrhea even while taking medications to prevent these side effects.

What other drugs will affect Inrebic

Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.

Other drugs may interact with fedratinib, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.